Achondroplasia is known as short-limbed dwarfism where by the process called ossification cartilage is converted into bones which are observed more in the ligaments like long bones of legs and arms. No cure or prevention remedies for the rising prevalence of achondroplasia dwarfism are major factor to fuel the growth of the global market of achondroplasia treatment. The increase in the number of achondroplastic dwarfism with no cure or prevention remedies is the major factor fueling the growth of the global market of achondroplasia treatment. Furthermore, leg lengthening surgeries are also done in special cases to prevent loss of function which is another factor propelling the target market growth. Moreover, various symptoms caused by achondroplasia can be an easily treated using drug which is boosting growth of the global market. However, lack of awareness about achondroplastic dwarfism among the people is having negative effect regraining the growth of the global achondroplasia treatment market.Achondroplasia Treatment Market was valued at US$ 120.4 million in 2024 and is projected to grow at a CAGR of 38.8 % to reach US$ 3208.6 million by 2034.

The report " Achondroplasia Treatment Market, By Product Type (RBM-007, TA-46, B-701, and Others), By End User (Hospital, Clinic, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Forecast to 2034"  

Key Highlights:

• In July 2019, Ascendis Pharma A/S which is a biopharmaceutical company has addressed some medical needs with the U.S. Food and Drug Administration (FDA) for investigation of new drug (IND) application to start the ACcomplisH Trial. ACcomplisH Trial is designed to evaluate the efficacy and safety of TransCon CNP in children with achondroplasia.

Key Market Insights from the report:          

Achondroplasia Treatment Market was valued at US$ 120.4 million in 2024 and is projected to grow at a CAGR of 38.8 % to reach US$ 3208.6 million by 2034. over the forecast period. The market report has been divided on the basis of product type, end-user, and region.

• By product type, the global achondroplasia treatment market is segmented into rbm-007, ta-46, b-701, and others.
• By end-user, the global achondroplasia treatment market is segmented into into hospital, clinic, and others.
• By region, North America dominates the market in terms of revenue due to increase in the research and development for the treatment of the achondroplasia.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on " Global Achondroplasia Treatment Market, By Product Type (RBM-007, TA-46, B-701, and Others), By End User (Hospital, Clinic, and Others), and by Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa)- forecast till 2034

The prominent player operating in the global achondroplasia treatment market includes Ascendis Pharma A/S, BioMarin Pharmaceutical Inc, and Ribomic Inc.

To know more

Contact Us:

Sales

Prophecy Market Insights

U.S: 1 860 531 2574

RoW: 91 7775049802

Email- sales@prophecymarketinsights.com

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com